Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Short-term Investments (2019 - 2025)

Historic Short-term Investments for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $84.1 million.

  • aTYR PHARMA's Short-term Investments rose 5414.18% to $84.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.1 million, marking a year-over-year increase of 5414.18%. This contributed to the annual value of $61.1 million for FY2024, which is 1924.31% down from last year.
  • Per aTYR PHARMA's latest filing, its Short-term Investments stood at $84.1 million for Q3 2025, which was up 5414.18% from $63.1 million recorded in Q2 2025.
  • Over the past 5 years, aTYR PHARMA's Short-term Investments peaked at $105.6 million during Q4 2021, and registered a low of $38.0 million during Q1 2021.
  • In the last 5 years, aTYR PHARMA's Short-term Investments had a median value of $71.7 million in 2024 and averaged $71.8 million.
  • Per our database at Business Quant, aTYR PHARMA's Short-term Investments soared by 61639.41% in 2021 and then crashed by 4680.09% in 2022.
  • aTYR PHARMA's Short-term Investments (Quarter) stood at $105.6 million in 2021, then crashed by 46.8% to $56.2 million in 2022, then soared by 34.64% to $75.6 million in 2023, then decreased by 19.24% to $61.1 million in 2024, then soared by 37.63% to $84.1 million in 2025.
  • Its last three reported values are $84.1 million in Q3 2025, $63.1 million for Q2 2025, and $66.0 million during Q1 2025.